Uncategorized
Oxford BioMedica to resume recruitment for three clinical trials
Oxford BioMedica has received approval from the U.S. Food and Drug Administration and ANSM, the French regulatory agency, to resume recruitment for three studies using existing clinical trial material, according to a press release.In June, Oxford BioMedica voluntarily stopped recruitment for the phase 1 RetinoStat, phase 1/2a StarGen and phase 1/2a UshStat phase studies as a precautionary measure while it investigated the detection of low concentrations of a potential impurity in its clinical trial material derived from a third-party raw material, the release said.